Teva Pharmaceutical Industries Limited vs Evotec SE: Examining Key Revenue Metrics

Teva vs. Evotec: A Decade of Revenue Shifts

__timestampEvotec SETeva Pharmaceutical Industries Limited
Wednesday, January 1, 20148949600020272000000
Thursday, January 1, 201512767700019652000000
Friday, January 1, 201616450700021903000000
Sunday, January 1, 201725763000022385000000
Monday, January 1, 201837540500018854000000
Tuesday, January 1, 201944643700016887000000
Wednesday, January 1, 202050092400016658000000
Friday, January 1, 202161803400015878000000
Saturday, January 1, 202275144800014925000000
Sunday, January 1, 202378142600015846000000
Monday, January 1, 202416544000000
Loading chart...

In pursuit of knowledge

A Tale of Two Pharmaceutical Giants: Teva and Evotec

In the ever-evolving pharmaceutical industry, Teva Pharmaceutical Industries Limited and Evotec SE stand as prominent players, each with unique trajectories over the past decade. From 2014 to 2023, Teva's revenue showcased a downward trend, decreasing by approximately 22% from its peak in 2016. This decline reflects the challenges faced by the company in maintaining its market dominance.

Conversely, Evotec SE has experienced a remarkable growth story, with its revenue increasing by over 770% during the same period. This surge underscores Evotec's strategic advancements and successful expansion in the biotech sector.

The contrasting revenue trends of these companies highlight the dynamic nature of the pharmaceutical landscape. As Teva navigates its challenges, Evotec's growth trajectory offers a glimpse into the potential for innovation and strategic positioning in the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025